The expression of PD-Ll protein as a prognostic factor in lung squamous cell carcinoma

被引:66
作者
Takada, Kazuki [1 ,2 ]
Okamoto, Tatsuro [1 ]
Toyokawa, Gouji [1 ]
Kozuma, Yuka [1 ]
Matsubara, Taichi [1 ]
Haratake, Naoki [1 ]
Akamine, Takaki [1 ]
Takamori, Shinkichi [1 ]
Katsura, Masakazu [1 ]
Shoji, Fumihiro [1 ]
Oda, Yoshinao [2 ]
Maehara, Yoshihiko [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka, Japan
关键词
Programmed cell death-ligand 1 (PD-L1); Immunohistochemistry; Lung; Squamous cell carcinoma; Ki-67; LIGAND; 1; EXPRESSION; TYROSINE KINASE INHIBITORS; PROGRAMMED DEATH LIGAND-1; GROWTH-FACTOR RECEPTOR; PD-L1; CLINICAL-SIGNIFICANCE; CANCER-IMMUNOTHERAPY; ANTI-PD-L1; ANTIBODY; CHEMOTHERAPY; ADENOCARCINOMA;
D O I
10.1016/j.lungcan.2016.12.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway-targeted immunotherapy has become the standard option of care in the management of lung cancer. The expression of the PD-L1 protein in lung cancer is expected to be a prognostic factor or to predict the response to PD-1-blocking antibodies. However, the association between PD-Ll positivity and the clinicopathological features and patient outcomes in lung squamous cell carcinoma (SCC) remains unclear because the definitive cut-off value for the expression of PD-Ll protein remains to be established. Materials and methods: The expression of PD-L1 protein in 205 surgically resected primary lung SCC patients was evaluated by immunohistochemistry with the antibody clone SP142. We generated a histogram to show the proportion of PD-Li-positive carcinoma cells, and set the cut-off values as 1%, 5%, 10% and 50%. Moreover, we examined the proliferative capacity of these tumors using Ki-67 immuno-histochemistry. Results: The samples from 106 (51.7%), 72 (35.1%), 61 (29.7%) and 37 (18.0%) patients were positive for the expression of PD-Ll protein at cut-off values of 1%, 5%, 10% and 50%, respectively. Fisher's exact test showed that, for almost all of the factors, PD-L1 positivity was not associated with the clinicopathological features with any of the four cut-off values. Univariate and multivariate survival analyses revealed that the PD-Ll-positive patients only had a poorer prognosis than the PD-L1-negative patients at the 1% cut-off value. The Ki-67 labeling index in the PD-Ll-positive patients was higher than that in the PD-Ll-negative patients. Conclusions: The expression of PD-Ll protein was associated with a poor prognosis in lung SCC patients. The 1% cut-off value for PD-Ll might become a better predictive marker than the other cut-off values. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:7 / 15
页数:9
相关论文
共 45 条
[1]   Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: A meta-analysis [J].
Ameratunga, Malaka ;
Pavlakis, Nick ;
Gebski, Val ;
Broad, Adam ;
Khasraw, Mustafa .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) :273-278
[2]  
[Anonymous], N ENGL J MED
[3]  
[Anonymous], MOD PATHOL
[4]  
Aquino SL, 2007, INT J MOL MED, V19, P495
[5]   Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer [J].
Azuma, K. ;
Ota, K. ;
Kawahara, A. ;
Hattori, S. ;
Iwama, E. ;
Harada, T. ;
Matsumoto, K. ;
Takayama, K. ;
Takamori, S. ;
Kage, M. ;
Hoshino, T. ;
Nakanishi, Y. ;
Okamoto, I. .
ANNALS OF ONCOLOGY, 2014, 25 (10) :1935-1940
[6]   Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung [J].
Boland, Jennifer M. ;
Kwon, Eugene D. ;
Harrington, Susan M. ;
Wampfler, Jason A. ;
Tang, Hui ;
Yang, Ping ;
Aubry, Marie Christine .
CLINICAL LUNG CANCER, 2013, 14 (02) :157-163
[7]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[8]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[9]  
Chen YB, 2012, TUMORI, V98, P751, DOI 10.1700/1217.13499
[10]   PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma [J].
Cooper, Wendy A. ;
Thang Tran ;
Vilain, Ricardo E. ;
Madore, Jason ;
Selinger, Christina I. ;
Kohonen-Corish, Maija ;
Yip, PoYee ;
Yu, Bing ;
O'Toole, Sandra A. ;
McCaughan, Brian C. ;
Yearley, Jennifer H. ;
Horvath, Lisa G. ;
Kao, Steven ;
Boyer, Michael ;
Scolyer, Richard A. .
LUNG CANCER, 2015, 89 (02) :181-188